| Tumor (N = 39) | Normal Control (N = 38) | p of Chi-Square test |
---|
 | N (examined) | + | N (examined) | + |  |
---|
 |  | n | % |  | n | % |  |
---|
IE | 32 | 31 | 97 | 27 | 17 | 63 | 0.0009 |
E/L | 25 | 21 | 84 | 28 | 6 | 21 | <0.0001 |
L | 27 | 15 | 56 | 28 | 11 | 39 | 0.2270 |
No Ab | 19 | 0 | 0 | 20 | 0 | 0 | -- |
CD34 | 16 | 0 | 0 | 9 | 0 | 0 | -- |
Actin | 28 | 0 | 0 | 29 | 0 | 0 | -- |
- Specific immunoreactivity to HCMV immediate early (IE) antigen and HCMV early and late (E/L) antigens were significantly higher in breast cancer cases than normal controls. Immunoreactivity to the HCMV late (L) antigen was higher in breast cancer than normal breast. No immunoreactivity was detected in any specimen when primary antibody was omitted. All specimens had specific immunoreactivity to vascular endothelial cells and smooth muscle cells with anti-CD34 and anti-smooth muscle actin antibodies, respectively, but no immunostaining of epithelial cells was observed with these antibodies.